Ofatumumab
- Generic Name
- Ofatumumab
- Brand Names
- Arzerra, Kesimpta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 679818-59-8
- Unique Ingredient Identifier
- M95KG522R0
- Background
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and...
- Indication
Ofatumumab is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
...
- Associated Conditions
- Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL) - Refractory, Clinically Isolated Syndrome (CIS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS), Progressive Chronic Lymphocytic Leukaemia (CLL), Recurrent Chronic Lymphocytic Leukaemia (CLL)
- Associated Therapies
- -
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06345157
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 75
- Registration Number
- NCT06167642
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
WOE of Anti-CD20 Therapies
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06121349
- Locations
- 🇺🇸
Novartis Investigational site, East Hanover, New Jersey, United States
Ofatumumab in AQP4-IgG Seropositive NMOSD
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Tang-Du Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT05504694
- Locations
- 🇨🇳
Tangdu Hospital, Xi'an, Shaanxi, China
Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
- Conditions
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT05414487
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 99
- Registration Number
- NCT05199571
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 40
- Registration Number
- NCT05171972
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT05090371
- Locations
- 🇺🇸
University of Mississippi Medical Center U of Mississippi, Jackson, Mississippi, United States
🇺🇸Alabama Neurology Associates PC CFTY720D2403, Birmingham, Alabama, United States
🇺🇸North Central Neurology Associates PC, Cullman, Alabama, United States
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
- Conditions
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 176
- Registration Number
- NCT05084638
- Locations
- 🇺🇸
Keck School of Medicine, Los Angeles, California, United States
🇺🇸Neurology Associates PA, Maitland, Florida, United States
🇺🇸Orlando Health Clinical Trials, Orlando, Florida, United States
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT04926818
- Locations
- 🇺🇸
Childrens Healthcare Of Atlanta ., Atlanta, Georgia, United States
🇺🇸Arkansas Childrens Hosp Rsch Inst ., Little Rock, Arkansas, United States
🇺🇸Childrens Hospital Los Angeles ., Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.